leilei shen

Dr. leilei shen


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2023 in Cancer Medicine
Verified
Journal Article
Open access
LSleilei shen
leilei shen
JGJuntang Guo
Juntang Guo
WZWeidong Zhang
Weidong Zhang
LZLianbin Zhang
Lianbin Zhang
XLXi Liu
Xi Liu
YLYang Liu
Yang Liu
Background: Adjuvant therapy for stage IB non‐small cell lung cancer remains debatable. In this real‐world study, we evaluate the efficacy and safety of adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) for resected stage IB lung adenocarcinoma.Methods: This real‐world study recruited 249 patients diagnosed with stage IB disease after surgical resection between January 2013 and September 2021. Sixty‐six (26.5%) patients received adjuvant targeted therapy (TKIs group), and 183 (73.5%) were enrolled in the clinical observation (CO) group. Propensity scores were matched to minimize the observed confounder effects between the two groups, and 59 patient pairs were matched. The primary endpoint was disease‐free survival (DFS).Results: In the TKI group, 38 (64.4%) patients chose to receive icotinib, 27.1% (16/59) received gefitinib, and 5 patients (8.5%) chose osimertinib. The median follow‐up time was 30.8 months (range: 7–107 months). Two (3.4%) patients in the TKI group and 10 (16.9%) in the CO group experienced disease relapse. The 3‐year DFS rates were 98.3% in the TKI group and 83.0% in the CO group (HR: 0.10; 95% CI: 0.01–0.78; p = 0.008). DFS differences were found in the entire cohort (p = 0.005) and the matched cohort (p = 0.024) between the two groups. Multivariate analysis showed that adjuvant EGFR‐TKIs was an independent factor for DFS (HR: 0.211; 95% CI: 0.045–0.979; p = 0.047), along with poor cell differentiation (HR: 5.256; 95% CI: 1.648–16.769; p = 0.005), and spread through air spaces (HR: 5.612; 95% CI: 1.137–27.700; p = 0.034). None of the patients discontinued EGFR‐TKIs owing to the low occurrence rate of treatment‐related serious adverse events.Conclusion: Adjuvant EGFR‐TKIs could significantly improve DFS among patients with stage IB lung adenocarcinoma compared with CO, with a safe and tolerable profile.

31 August 2023 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
ZZZirui Zhu
Zirui Zhu
YLYou Liu
You Liu
HXHengliang Xu
Hengliang Xu
HNHaoyong Ning
Haoyong Ning
YXYanmin Xia
Yanmin Xia
LSleilei shen
leilei shen
Background: Combined large cell neuroendocrine carcinoma (C-LCNEC) has a poor prognosis and there is no consensus about the treatment regimen for both LCNEC and C-LCNEC patients. Case presentation: The patient was a 47-year-old female who received surgical resection. The postoperative histology and staging of the tumor suggested C-LCNEC with adenocarcinoma and squamous cell carcinoma and T2aN0M0 stage IB. Next-generation sequencing test showed KIF5B/RET fusion mutation without EGFR, ALK, RB1, and TP53 alterations. Adjuvant chemotherapy with 4-cycle docetaxel plus carboplatin was given and brain metastasis occurred after 10 months. Conclusions: C-LCNEC with adenocarcinoma and squamous cell carcinoma is rare and highly aggressive cancer. Surgical resection and adjuvant chemotherapy with SCLC regimen may improve the disease-free survival and overall survival. The accumulation of similar cases will clarify the profile and management of the disease.

17 May 2024 in International Journal of Surgery
Verified
Journal Article
Open access
YLYunze Liu
Yunze Liu
HRHong Ren
Hong Ren
YPYanbin Pei
Yanbin Pei
LSleilei shen
leilei shen
JGJuntang Guo
Juntang Guo
YLYang Liu
Yang Liu
Background: Clinical differentiation between pulmonary metastases and noncalcified pulmonary hamartomas (NCPH) often presents challenges, leading to potential misdiagnosis. However, the efficacy of a comprehensive model that integrates clinical features, radiomics, and deep learning (CRDL) for differential diagnosis of these two diseases remains uncertain. Objective: This study evaluated the diagnostic efficacy of a CRDL model in differentiating pulmonary metastases from NCPH. Methods: The authors retrospectively analyzed the clinical and imaging data of 256 patients from the First Medical Centre of the General Hospital of the People’s Liberation Army (PLA) and 85 patients from Shanghai Changhai Hospital, who were pathologically confirmed pulmonary hamartomas or pulmonary metastases after thoracic surgery. Employing Python 3.7 software suites, the authors extracted radiomic features and deep learning (DL) attributes from patient datasets. The cohort was divided into training set, internal validation set, and external validation set. The diagnostic performance of the constructed models was evaluated using receiver operating characteristic (ROC) curve analysis to determine their effectiveness in differentiating between pulmonary metastases and NCPH. Results: Clinical features such as white blood cell count (WBC), platelet count (PLT), history of cancer, carcinoembryonic antigen (CEA) level, tumor marker status, lesion margin characteristics (smooth or blurred), and maximum diameter were found to have diagnostic value in differentiating between the two diseases. In the domains of radiomics and DL. Of the 1130 radiomics features and 512 DL features, 24 and 7, respectively, were selected for model development. The area under the ROC curve (AUC) values for the four groups were 0.980, 0.979, 0.999, and 0.985 in the training set, 0.947, 0.816, 0.934, and 0.952 in the internal validation set, and 0.890, 0.904, 0.923, and 0.938 in the external validation set. This demonstrated that the CRDL model showed the greatest efficacy. Conclusions: The comprehensive model incorporating clinical features, radiomics, and DL shows promise for aiding in the differentiation between pulmonary metastases and hamartomas.

7 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SWShiwei Wang
Shiwei Wang
MXMingyue Xu
Mingyue Xu
YLYou Liu
You Liu
XHXiaoming Hou
Xiaoming Hou
ZGZhaofeng Gao
Zhaofeng Gao
LSleilei shen
leilei shen
Although some studies have assessed the correlation between clinicopathological features and programmed death-ligand 1 (PD-L1) in patients with non-smallcell lung cancer (NSCLC), few studies have focused on computed tomography (CT) signs. The results of some previous studies are inconsistent and contradictory. Therefore, this study aimed to analyze the clinicopathological and CT features of NSCLC patients with different PD-L1 expression levels. This retrospective analysis included 911 NSCLC patients who undergone pulmonary resection, and most of them were early-stage. PD-L1 expression was assessed by immunohistochemistry with the Dako PD-L1 22C3 pharmDx kit. Clinicopathological features and CT signs were investigated according to different PD-L1 expression levels. The prevalence of PD-L1 expression in the resected NSCLC patients was 46.9% (427/911), with 381 patients low expression (41.8%) and 46 patients high expression (5%). Male sex, current smoking status, higher positron emission tomography-computed tomography (PET-CT) SUVmax, and elevated serum carcinoembryonic antigen levels were more frequently observed in patients with high PD-L1 expression. The frequencies of squamous cell carcinoma type, spread through air space (STAS), TP53 mutations, advanced pathological stages, and micropapillary/solid subtype were significantly higher in patients with PD-L1 positive tumors (TPS ≥ 1%) than in those with PD-L1 negative tumors (TPS < 1%). ALK rearrangement was higher in patients with low-expression, and PD-L1-positive patients had bigger tumor diameter. The proportion of solid nodules and consolidation to tumor were higher in high-expression than those in the low- or negative expression PD-L1 patients. Regarding structural characteristic features, there were no differences in the frequency of irregular borders, pleural retraction, air bronchograms, bubble-like lucency or cavities, and vascular convergence among the three groups. The frequency of lobulated margins and spiculation was significantly higher in patients with PD-L1 positive tumors than in those with PD-L1 negative tumors. Patients with PD-L1 expression in NSCLC often exhibit certain clinicopathological characteristics. CT features may not reliably correlate with PD-L1 expression across different stages of lung cancer. Immunohistochemistry (IHC), using relevant kits, remains essential for further evaluation of PD-L1 expression levels.

23 February 2023 in Cancer Imaging
Verified
Journal Article
Open access
PDF file
XHXiaoming Hou
Xiaoming Hou
HCHan Chen
Han Chen
YLYou Liu
You Liu
SGSandong Gong
Sandong Gong
MZMeizi Zhudai
Meizi Zhudai
LSleilei shen
leilei shen
Background: Although some studies have assessed the correlation between computed tomography (CT) features and anaplastic lymphoma kinase (ALK) rearrangement in patients with non-small-cell lung cancer (NSCLC), few have focused on early-stage patients. The results of some previous studies are inconsistent and contradictory. Therefore, this study aimed to analyze the clinicopathological and CT features of patients with early-stage NSCLC harboring ALK rearrangement. Methods: This retrospective analysis included 65 patients with ALK rearrangement and 629 ALK-negative patients. All patients had surgically resected NSCLC and were diagnosed with stage IA or stage IIB NSCLC. Clinicopathological features and CT signs, including tumor size and density, consolidation tumor ratio (CTR), lesion location, round or irregular shape, lobulated or spiculated margins, air bronchograms, bubble-like lucency or cavities, and pleural retraction, were investigated according to different genotypes. Results: The prevalence of ALK rearrangement in patients with early-stage NSCLC was 9.3% (65/694). Patients with ALK rearrangement were significantly younger than those without ALK rearrangement (P = 0.033). The frequency of moderate cell differentiation was significantly lower in tumors with ALK rearrangement than in those without ALK rearrangement (46.2% vs. 59.8%, P = 0.034). The frequency of the mucinous subtype was significantly higher in the ALK-positive group than in the ALK-negative group (13.8% vs. 5.4%, P = 0.007). No significant differences were found in any CT signs between the ALK-positive and ALK-negative groups. Conclusions: Patients with ALK-positive lung cancer may have specific clinicopathological features, including younger age, lower frequency of moderate cell differentiation, and higher frequency of the mucinous type. CT features may not correlate with ALK rearrangement in early-stage lung cancer. Immunohistochemistry or next-generation sequencing is needed to further clarify the genomic mutation status.

30 December 2020
Verified
Journal Article
Closed access
LSleilei shen
leilei shen
TYTianyang Yun
Tianyang Yun
JGJuntang Guo
Juntang Guo
YLYang Liu
Yang Liu
CLChaoyang Liang
Chaoyang Liang